influenza vaccine

High‑Dose Influenza Vaccine Reduces Hospitalisations in Older Adults

By MedXY 11/11/2025

A prespecified pooled analysis of two large randomised pragmatic trials (DANFLU-2 and GALFLU) found high‑dose influenza vaccine reduced hospitalisation for influenza or pneumonia by 8.8% versus standard‑dose in adults ≥65 years, with larger effects for laboratory‑confirmed influenza.

Infectious Diseases news Public Health

Updated Evidence for Covid-19, RSV, and Influenza Vaccines in the 2025-2026 Season: A Comprehensive Review

By MedXY 10/31/2025

A systematic review supports the continued safety and effectiveness of Covid-19, RSV, and influenza vaccines for the upcoming 2025-2026 season, highlighting detailed vaccine efficacy, safety profiles, and recommendations for at-risk populations.

Infectious Diseases news Pediatrics

Evaluating the Incremental Benefit of Two Versus One Dose of Influenza Vaccine in Influenza-Naive Children Under Nine: A Systematic Review and Meta-Analysis

By MedXY 10/04/2025

This systematic review and meta-analysis assess the additional protection from a second dose of influenza vaccine in vaccine-naive children under nine years old, highlighting significant benefits particularly for those under three years.

Cardiology Public Health Specialties

High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial and Related Evidence

By MedXY 09/27/2025

This review synthesizes evidence on high-dose versus standard-dose influenza vaccines for cardiovascular outcomes in older adults, focusing on the large DANFLU-2 trial and complementary studies, highlighting modest cardiovascular benefits and implications for clinical practice.

Clinical Updates Internal Medicine news Public Health Respiratory Specialties

High-Dose vs Standard-Dose Influenza Vaccine in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial

By MedXY 09/06/2025

The DANFLU-2 trial demonstrates that high-dose influenza vaccine reduces cardiovascular and cardiorespiratory hospitalizations compared to standard-dose in adults ≥65 years, with similar benefits across subgroups including heart failure and atherosclerotic cardiovascular disease.

Cardiology Public Health Specialties

Enhanced Protection in Heart Failure: High-Dose Influenza Vaccine Outperforms Standard Dose in the DANFLU-2 Trial

By MedXY 09/06/2025

The DANFLU-2 trial reveals that high-dose influenza vaccine significantly reduces hospitalization for influenza and cardiovascular events in older adults, including those with heart failure, compared to the standard-dose vaccine.

Cardiology Clinical Updates Public Health Specialties

PANDA II Trial Confirms Influenza Vaccination as Essential Intervention for Acute Heart Failure Patients

By MedXY 09/03/2025

The PANDA II study demonstrates that influenza vaccination significantly reduces mortality and rehospitalization in acute heart failure patients, supporting its inclusion as a standard component of heart failure management worldwide.

Cardiology Public Health Specialties

High-Dose Influenza Vaccines Cut Hospitalizations: Landmark Trials Shape Cardiovascular Prevention

By MedXY 08/30/2025

Two massive randomized trials show high-dose flu vaccines reduce influenza-related and cardiorespiratory hospitalizations in older adults, reinforcing vaccination as a vital cardiovascular prevention strategy.

Family Medicine & Nutrition Medical News news Public Health Specialties

Comparing the Effectiveness of Influenza Vaccines: Subunit Vaccine vs. Split-Virion Vaccine

By MedXY 08/04/2025

A prospective study shows split-virion vaccines offer significantly higher protection against influenza than subunit vaccines in adults 50 and older, highlighting the importance of vaccine selection.